Cytokinetics Plans $550 Million Private Placement of Convertible Senior Notes

Cytokinetics Offering Convertible Senior Notes: Cytokinetics announced a private placement offering of $550 million in convertible senior notes due 2031, with an option for initial purchasers to buy an additional $82.5 million. The notes will be senior, unsecured obligations and will accrue interest payable semi-annually.

Use of Proceeds: The company plans to use the proceeds to fund the cash portion of note exchange transactions, support the commercial launch and development of aficamten, advance its research pipeline, and for general corporate purposes.

Note Exchange Transactions: Cytokinetics intends to exchange a portion of its outstanding 2027 convertible senior notes in privately negotiated transactions, which may involve significant market activity affecting the price of its common stock.

Forward-Looking Statements: The press release includes forward-looking statements regarding the offering and its potential impact, emphasizing that actual results may differ due to various risks and uncertainties, including market conditions and business risks.